New IP resource for Pharma, Biotech and Chem and You can’t always get what you want – restrictions on remedies in IP litigation

Another quick excerpt from the new book on Global IP soon to be published by Oxford:

In Australia, China, Italy, the Netherlands, and the United Kingdom, damages may be refused even if there is patent infringement if the test for ‘innocent infringement’ is met.  There is no provision for innocent infringement in Canada, the United Statesor France.  However, an intention to infringe is required for Chinese and French criminal proceedings for patent infringement.

As before, this is a short excerpt from one of the overview summary sections.

Just to recap, it’s a detailed and strategic look at intellectual property and related issues in the pharmaceutical, biotechnology and chemical industries.  It covers 11 jurisdictions, has a Europe overview section and will be published by Oxford University Press.  It is topic based, so that you can see how the same issue is dealt with across the globe in one spot.

Oxford has kindly granted a 20% discount for readers of IP Think Tank. To claim your discount, just click this link (Pharmaceutical, Biotechnology and Chemical Inventions) and enter the code ‘ALBUCK10′ , or call the team at Oxford on +44 (0) 1536 741727 and use the code ‘ALBUCK10’.  (Note:  this offer is only available on orders placed direct with Oxford University Press and is not available through any other supplier.)

Just to give you a little more background, the book will be published in a 2 volume set, with about 2,500 pages.  It’s designed for the in-house team – to make things way easier than they are today.

Finally, thanks again to our incredible contributor team, each of whom are amongst the very best in the world:

  • Pravin Anand, Anund and Anund, India
  • John Bateman, Kenyon & Kenyon, USA
  • Susan Beaubien, Moffat & Co, Macera & Jarzyna LLP, Canada
  • Theo Bodewig, Humboldt University, Germany (Consultant Editor)
  • Simon Cohen, Taylor Wessing, UK
  • Wayne Condon, Griffith Hack, Australia
  • Marina Couste, Howrey LLP, France
  • Robert A. Dormer, Hyman, Phelps & McNamara, P.C., United States
  • Atsushi Hakoda, Nakamura & Partners, Japan
  • Juany Huang, Panawell and Partners LLC, China
  • Reuben E. Jacob, R. G. C. Jenkins, UK
  • Fabrizio Jacobacci, Studio Legale Jacobacci & Associati, Italy
  • Kurt R. Karst, Hyman, Phelps & McNamara, P.C., United States
  • Klaus Kupka, Taylor Wessing, Germany
  • David C. Musker, R. G. C. Jenkins, UK
  • Cyra Nargolwalla, Cabinet Plasseraud, France
  • Nina Resinek, Taylor Wessing, Germany
  • Toshio Takizawa, Nakamura & Partners, Japan
  • Koichi Tsujii, Nakamura & Partners, Japan
  • Klaus Schweitzer, Plate Schweitzer Zounek, Patentanwaelte, Germany
  • Deborah Somerville, Kenyon & Kenyon, USA
  • Paul Steinhauser, Arnold Siedsma, Netherlands
  • Nigel Stoate, Taylor Wessing, UK
  • Rosie Stramandinoli, Griffith Hack, Australia
  • Otto Swens, Steinhauser Hoogenraad, Advocaten, The Netherlands
  • Andreas Walkenhorst, Tergau & Pohl Patentanwälte, Germany
  • William Yang Panawell & Partners LLC, China
  • Federico Zanardi Landi, Studio Legale Jacobacci & Associati, Italy

One Comment on “New IP resource for Pharma, Biotech and Chem and You can’t always get what you want – restrictions on remedies in IP litigation

  1. Pingback: Pharma & Biotech Global Week in Review 22 September 2010 from IP Think Tank

%d bloggers like this: